Sinovac Biotech: Approval granted for the market application of quadrivalent influenza subunit vaccine.
Zhonghui Biotech announced that the China National Medical Products Administration has approved the company's new drug application for a quadrivalent influenza virus subunit vaccine for the 6-35 month age group. This vaccine has become the first and only quadrivalent influenza virus subunit vaccine approved for the entire population in China.
Latest